Obinutuzumab as Initial or Second-Line Therapy in Patients With Primary Membranous Nephropathy.

ABSTRACT:

Introduction

B-cell lymphocytes have been demonstrated to play a key role in the pathogenesis underlying membranous nephropathy (MN). The aim of this study was to evaluate the therapeutic efficacy and safety of Obinutuzumab, a glycoengineered type II anti-CD20 monoclonal antibody in individuals with MN.

Methods

We retrospectively analyzed data from 59 consecutive patients with primary MN who provided consent to receive Obinutuzumab and were followed for at least 6 months. The primary outcomes were complete (proteinuria <0.3 g/d) or partial (proteinuria <3.5 g/d with ≥ 50% reduction) remission of proteinuria.

Results

Twenty patients received Obinutuzumab as initial therapy, and 39 patients were previously treated with at least 1 immunosuppressant (second-line therapy).

SUBMITTER: Su X 

PROVIDER: S-EPMC11328588 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature